Clinical and prognostic importance of XIAP and USP8 in advanced stages of non-small cell lung cancer
| Autor: | Baykara, M., Yaman, M., Buyukberber, S., Tufan, G., Demirci, U., mustafa benekli, Coskun, U., Ozet, A., Umit Bagriacik, E. |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Aged 80 and over Male Chi-Square Distribution Lung Neoplasms Time Factors Endosomal Sorting Complexes Required for Transport Antineoplastic Agents X-Linked Inhibitor of Apoptosis Protein Kaplan-Meier Estimate Middle Aged Disease-Free Survival respiratory tract diseases Treatment Outcome Risk Factors Carcinoma Non-Small-Cell Lung Case-Control Studies Endopeptidases Multivariate Analysis Biomarkers Tumor Humans Female Ubiquitin Thiolesterase Aged Neoplasm Staging |
| Zdroj: | Europe PubMed Central Scopus-Elsevier |
| ISSN: | 1107-0625 |
| Popis: | To investigate the relationship of the apoptosis regulators X-linked inhibitor of apoptosis (XIAP) and ubiquitin specific protease 8 (USP8) with clinical parameters, survival and response to chemotherapy in patients with advanced stages of non-small cell lung cancer (NSCLC).The study included 34 NSCLC patients (28 females, 6 males) and 44 healthy individuals (17 males, 27 females) as a control group. XIAP and USP8 levels were determined by ELISA.The median serum XIAP level of the patients and the control group showed no significant difference. USP8 level was higher in patients than in controls (p0.0001). In univariate analysis, there was no significant relationship between XIAP and USP8 serum levels and age, sex, performance status, weight loss, stage of disease, histopatological type and response to chemotherapy. Response to chemotherapy did not differ between the high and low XIAP and USP8 groups . There was no significant difference in progression- free survival (PFS) (p=0.432 and p=0.50, respectively) and overall survival (OS) (p=0.989 and p=0.90, respectively) between the low and high XIAP and USP8 groups.No relationship was found in serum XIAP and USP8 levels with clinical parameters, response to chemotherapy, PFS and OS in patients with advanced stages of NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|